USPTO Patent Applications - Pharma (A61K)

Phytic Acid-Based Ternary Complex Biomimetic Nanomaterial for Tumor Targeting

The USPTO published patent application US20260108641A1, filed July 25, 2024 (application No. 19487095), disclosing a phytic acid (PA)-based ternary complex biomimetic nanomaterial formed by connecting proteins or polypeptides to PA using metal cations as bridging agents. The invention constructs a novel nanotheranostic probe with high biocompatibility that can reassemble and persistently accumulate at tumor sites, enabling coordination loading of imaging/therapeutic metal ions for long-lasting tumor imaging, treatment, or integrated diagnosis and treatment.

High Molecular Weight Multi-Arm Polymers and Medical Hydrogels - US20260108634A1

Boston Scientific Scimed, Inc. filed patent application US20260108634A1 on October 21, 2025, covering high molecular weight multi-arm polymers and medical hydrogels formed therefrom. The application names Yen-Hao Hsu, Marc Plourde, and Heather Cirka as inventors and specifies reactive multi-arm polymers with molecular weights exceeding 10,000 Daltons for cross-linked hydrogel kits. Patent applications do not grant enforceable rights and create no immediate compliance obligations for third parties.

Boston Scientific Scimed Ether-Containing Radiopaque Hydrogel Patent

Boston Scientific Scimed, Inc. filed patent application US20260108635A1 on October 21, 2025 (Application No. 19364325) for iodinated polyamino compounds comprising a polyamino moiety coupled to an iodinated aromatic moiety through an ether linkage, optionally including an amide group. The application also covers systems for forming hydrogels using these compounds with a reactive polymer that forms crosslinks, and methods of treatment using such systems. Inventors are Rick William Dorn, Cristian Parisi, Joseph Thomas Delaney Jr., and Yen-Hao Hsu.

68Ga- and 64Cu-NODAGA-E[c(RGDyK)]2 PET Tracers for Angiogenesis Imaging

Rigshospitalet filed patent application US20260108638A1 disclosing two novel PET tracers — 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 — for clinical imaging of neo-angiogenesis in humans. The application (No. 19413437) was published April 23, 2026 under CPC classification A61K 51/0482, with inventors Andreas Kjær, Jacob Madsen, Malene Brandt-Larsen, and Jytte Oxboel listed. The abstract claims both Ga-68 and Cu-64 chelates bound to the NODAGA-E[c(RGDyK)]2 targeting moiety for diagnostic PET applications.

PSMA and TSPO Compounds Diagnose Peripheral Nervous System Injuries

USPTO published patent application US20260108637A1 on April 23, 2026, covering methods for diagnosing peripheral nervous system (PNS) neuropathy by administering TSPO-targeting or PSMA-targeting compounds to a subject and taking an image. The application (filed December 2, 2025, Application No. 19405641) names Martin Gilbert Pomper, Catherine Foss, Sami Tuffaha, and William Michael Padoveno as inventors. CPC classifications indicate pharmaceutical composition applications under A61K.

Patent Application for Non-Alcoholic Steatohepatitis Diagnostic Complex

USPTO published patent application US20260108639A1 on April 23, 2026, covering a diagnostic complex for non-alcoholic steatohepatitis (NASH). The complex comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator, enabling binding to asialoglycoprotein receptors for radiological diagnosis. The application was filed on October 21, 2024, under application number 18921265, naming six inventors including Hung-Wen YU, Mei-Hui WANG, and others.

AAV Capsid Variants and Uses Thereof Patent Application

USPTO published patent application US20260108626A1 for AAV capsid variants on April 23, 2026. The application, originally filed on August 6, 2025, names seven inventors including Mathieu Emmanuel Nonnenmacher, Tyler Christopher Moyer, Jiangyu Li, Dan Richard Laks, Brett Hoffman, Elisabeth Knoll, and Yanqun Shu. The disclosure covers compositions and methods for preparing adeno-associated virus capsid protein variants used in gene therapy and biopharmaceutical applications.

BIOCOMPATIBLE NANOPARTICLES AND USES THEREOF

A process for preparing polymeric monodispersed reduced nanohydrogels (NHGs) comprises combining monomers, macromonomer, a cross-linker, and a surfactant to obtain a precursor mixture; heating the precursor mixture to at least 40°C; adding an initiator; and performing an NHG reduction step. The application US20260108625A1 was published on April 23, 2026, naming inventors Gerardo BYK, Eswaran LAKSHMANAN, Cyril Joseph COHEN, and Maria RADMAN, with a filing date of September 27, 2023.

Nucleic Acid Storage and Transport at Ambient Temperatures

Board of Regents, The University of Texas System, published patent application US20260108624A1 (filed September 25, 2023) for liquid and substantially solid film compositions enabling long-term storage, transport, and delivery of nucleic acids and other molecules without ultralow temperature requirements. Inventors Trang Doan and Maria Croyle claim compositions that maintain nucleic acid integrity at ambient temperatures, potentially eliminating cold-chain storage needs for biological materials.

DNA Plasmids for Retroviral CAR TCR Manufacturing

USPTO published patent application US20260108629A1 filed by Edward Liao on August 13, 2025, covering DNA molecules such as transfer plasmids useful for manufacturing packaged retroviral vectors encoding therapeutic proteins including chimeric antigen receptors (CARs) and T cell receptors (TCRs). The application specifies that the encoded retroviral transcript includes a transgene, an EF1α promoter without the EF1α intron, operably linked to the transgene, and a Rev response element (RRE).

MIT Non-Pegylated Lipid Nanoparticles, Therapeutic Applications

Massachusetts Institute of Technology published patent application US20260108622A1 on April 23, 2026, claiming non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles for therapeutic applications. The application (No. 19364970) has a priority filing date of October 21, 2025, and covers CPC classifications including A61K 47/6911, A61K 9/0019, A61K 31/7105, and related pharmaceutical categories. Inventors include Paula T. Hammond-Cunningham, Namita Rajesh Nabar, and Deeksha Kumaresh.

sgRNA for Utrophin Activation to Treat Duchenne Muscular Dystrophy

Kunming University of Science and Technology published patent application US20260108628A1 covering an sgRNA capable of activating utrophin transcription and translation in human and mouse systems, as a therapeutic approach for Duchenne muscular dystrophy. The application, filed January 18, 2024, contains DNA sequences represented by SEQ ID NOS: 1-20 and 21-39. The invention provides a gene therapy option targeting endogenous utrophin upregulation as an alternative to dystrophin replacement.

Conjugation Linkers Cell Binding Molecule-Drug Conjugates Hangzhou DAC Biotech

USPTO published patent application US20260108619A1 filed by Hangzhou DAC Biotech Co., Ltd. on October 14, 2025. The application covers novel conjugation linkers having propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl groups, and their use for attaching cytotoxic agents to cell-binding molecules such as antibodies to form antibody-drug conjugates (ADCs).

USPTO Publishes A1 Application for Mucoadhesive Polymeric Prodrug Delivery System

The USPTO published application US20260108615A1 on April 23, 2026, covering a mucoadhesive polymeric prodrug system using partially succinated polyvinyl alcohol (PVA-SA) that self-assembles into 50–260 nm particles for controlled drug delivery. The prodrug forms ester and/or amide linkages with biologically active compounds including doxorubicin (DOX), cysteamine (CYS), ketoprofen (KETO), and 4-hydroxybenzyl alcohol (HBA), enabling adjustable drug release and improved mucoadhesive properties. The application (No. 18697611) was originally filed on September 29, 2022, by inventors Abdelghafour, Szabó, Janovák, Dékány, and Rovó.

Immobilized Endoglycosidase Fusion Protein and Use Thereof

USPTO published patent application US20260108614A1 on April 23, 2026, covering a method for preparing site-specific antibody-drug conjugates using an immobilized endoglycosidase fusion protein. The method enables covalent attachment of oxazoline oligosaccharides to antibodies at N-glycosylation sites in the Fc region under enzymatic catalysis. The application also discloses the endoglycosidase fusion protein with Halo tag and/or His tag, an immobilized version on a support, and a prepacked column for antibody conjugate purification. Inventors: Cao LV, Jinduo YUAN, Gang QIN, Meijun XIONG. Application No. 19249408, filed June 25, 2025.

Auto-Tuning Drug Regulator Construct, US20260108617A1

USPTO published patent application US20260108617A1 for an auto-tuning drug regulator construct with a filing date of January 17, 2024. The invention describes a chemical construct comprising a biorecognition component, an incapacitation component, and an active drug component, where drug release is triggered by the presence or absence of a target enzyme. Six inventors are named: Tapash Jay Sarkar, Edward Njoo, Lorelei Xia, Akira Yamamoto, Zachary Bashkin, and Warren Chang. This document is a publication announcement only and creates no compliance obligations.

Antibody-Conjugates for Targeting of Tumours Expressing Trop-2

USPTO published patent application US20260108620A1 covering antibody-conjugate compounds structured to target Trop-2-expressing tumours. Six inventors are named, including Maria Antonia Wijdeven, Jorge Merijn Mathieu Verkade, Jorin Hoogenboom, Sander Sebastiaan van Berkel, Floris Louis van Delft, and Petrus Josephus Jacobus Maria van de Sande. The application was filed on August 7, 2025, and published April 23, 2026, specifying therapeutic payloads including taxanes, anthracyclines, camptothecins, maytansinoids, and pyrrolobenzodiazepine dimers.

Compounds and Compositions as VHL Ligands and STAT3 Degraders

USPTO published patent application US20260108613A1 on April 23, 2026, covering compounds and compositions of Formula I or II as VHL ligands and bifunctional degraders for STAT3 protein degradation. The application, filed December 19, 2025, by inventors including Shaomeng Wang and ten co-inventors, lists CPC classifications in A61K, C07D. This is a patent application seeking protection for specific pharmaceutical compounds rather than a granted patent or regulatory action.

CAR T Cell Compositions for Cancer Treatment, Washington University

Washington University has obtained a US patent application publication (US20260108604A1) for CAR T cell compositions in which FOXO3 expression is silenced. Filed on September 15, 2023, under Application No. 19111411, the patent covers compositions and methods for treating cancer by silencing FOXO3 to prevent or delay CAR T cell dysfunction associated with chronic antigen stimulation. Inventor is Nathan Singh.

Antibodies Binding OX40L Combined with Hyaluronidase, Inflammatory Treatment

The USPTO published patent application US20260108603A1 on April 23, 2026, disclosing compositions and combinations comprising an antibody that binds OX40L and a hyaluronidase or variant thereof for treating inflammatory disorders or diseases in human patients. Inventors are Aaron NOYES and Rebecca Lucille DABORA, with an original filing date of October 17, 2025, and application number 19361800. This A1 publication makes the application publicly accessible for examination purposes.

DCTY Biotech EGFRvIII CAR Antibody Application, Apr 23

Beijing DCTY Biotech Co., Ltd. has filed Application US20260108607A1 with the USPTO covering an antibody targeting EGFRvIII and its use in chimeric antigen receptor (CAR) cell immunotherapy. The application, filed August 4, 2023 under Application No. 19100824, names Shuang Li, Zishan Zhou, Yujie Song, and Rong Zhang as inventors. The published application provides claims to the antibody or antigen-binding fragment thereof, a CAR incorporating the fragment, and therapeutic and detection uses. Biopharmaceutical companies developing CAR-T or targeted cancer immunotherapies targeting EGFRvIII should review this published application for potential freedom-to-operate considerations.

US20260108574A1 Herbal Composition for Metabolic Disorders

The USPTO has published patent application US20260108574A1, filed October 16, 2025 by M/S Natural and Essential Oils Private Limited, disclosing a herbal composition for treating metabolic disorders in mammals including central obesity, high blood pressure, high blood sugar, stress-induced fatigue, and type 2 diabetes. The composition comprises extracts of Dolichos lablab, Achyranthes aspera, and Cinnamomum zeylanicum or Cinnamomum cassia, standardized to contain proanthocyanidins, saponins, polyphenols, and tannins. The application describes methods of preparation and therapeutic effects including enhanced adiponectin and HDL levels.

Calluna Vulgaris for Urinary Tract Infection Treatment

USPTO published patent application US20260108573A1 by inventor Heather Florio on April 23, 2026, covering methods and compositions of Calluna vulgaris for the prevention and treatment of urinary tract infections. The application (No. 19322118) was filed on September 8, 2025 and classifies under CPC codes A61K 36/45, A61K 9/14, and A61P 13/02.

Nrf2 Activation Compositions, Treat Inflammation, Oxidative Stress

USPTO published patent application US20260108575A1 on April 23, 2026, filed by Brooks Michael Hybertson and Joe Milton McCord under Application No. 19370063. The application covers compositions containing phytochemicals that activate Nrf2 pathways for preventing or treating health conditions associated with inflammation or oxidative stress. The filing date was October 27, 2025, and CPC classifications include A61K 36/53, A61K 31/352, A61K 36/906, and A61K 45/06.

Method for Preparing Biotic Superparamagnetic Nanoparticles Derived from Colchicum Ritchii

USPTO has published patent application US20260108578A1 for a method of preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract. The application, filed on January 17, 2025 by inventors Veeramoni Chinnadurai, Khalid A. Al-Numair, and Mohammed A. Alsaif, describes combining the plant extract with ferric chloride solution followed by sodium hydroxide to form superparamagnetic nanoparticles. The invention is classified under CPC codes A61K 36/88, A61K 9/5115, A61K 9/5192, A61K 47/02, A61P 3/04, and A61P 3/10, indicating applications in pharmaceutical preparations for metabolic disorders.

BioDevas Laboratoires Patent for Aromatic Plant Extract Flea Treatment Composition

BioDevas Laboratoires has been granted USPTO Application US20260108576A1 for a composition against ectoparasites, specifically fleas affecting domestic mammals. The composition comprises a mixture of extracts from aromatic plants, including lemon balm, thyme, rosemary, wormwood, and lemongrass. The application was filed on December 22, 2025, under Application No. 19428445, with inventors François BLUA and Jean Louis BLUA. The patent covers veterinary and pharmaceutical compositions incorporating the extract mixture, along with animal food products containing the composition and methods for preparing and administering the composition for flea prevention or treatment.

US20260108577A1: Biotic Superparamagnetic Nanoparticles from Colchicum Ritchii

USPTO published patent application US20260108577A1 on April 23, 2026, disclosing a method for preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract combined with ferric chloride solution and sodium hydroxide solution. The application names VEERAMANI CHINNADURAI, KHALID S. AL-NUMAIR, and MOHAMMED A. ALSAIF as inventors, with a filing date of October 17, 2024, and application number 18918527. CPC classifications indicate pharmaceutical applications including weight management (A61P 3/04) and diabetes treatment (A61P 3/10).

Akkermansia Muciniphila Akk11 Strain Regulates Blood Glucose and Blood Lipid

USPTO published patent application US20260108566A1 for Akkermansia muciniphila Akk11 (deposit number CCTCC NO: M 2024119). The application claims the strain uses mucin as the sole carbon and nitrogen source to regulate glucose and energy metabolism, protecting intestinal epithelial cells and mucus layer while regulating blood glucose and blood lipid levels, with potential applications for obesity and metabolic disorder treatment. The patent application names six inventors and was filed on 2024-07-08.

Nihon Pharmaceutical Muscle Proteoglycan Patent, Apr 23

NIHON PHARMACEUTICAL CO., LTD. has filed patent application US20260108563A1 titled 'COMPOSITION FOR IMPROVING OR MAINTAINING MUSCLE QUANTITY OR MUSCLE STRENGTH', published April 23, 2026. The invention covers a novel method for producing proteoglycan by immersing a biological sample in an aqueous surfactant solution, and its use in improving muscle quantity or strength and preventing obesity or reducing body fat percentage. The application was originally filed on August 3, 2023 under application number 19100791, with Tatsuya Wada listed as inventor.

Stem Cell Microglia Transplant Leukodystrophy Treatment

USPTO published patent application US20260108560A1 titled 'Transplanting Stem Cell-Derived Microglia to Treat Leukodystrophies' on April 23, 2026. The application covers myeloid cells, microglial progenitor cells, and microglia-like cells in which mutant genes have been repaired or replaced, and methods of using such cells to treat disease. Seven inventors are named including Mathew Blurton-Jones, Hayk Davtyan, Jean Paul Chadarevian, Robert Spitale, Sunil Gandhi, Jonathan Hasselmann, and Whitney England.

Composition for Neural Precursor Cell Therapy, Singapore

The United States Patent and Trademark Office published patent application US20260108561A1, filed by National University of Singapore (assignee) on October 3, 2023. The application covers a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into neurological injury or disease sites, comprising a gel forming molecule and a CCR5 antagonist. Also disclosed are methods of treating neurological injuries using NPC transplantation with this composition and a kit containing the composition, artificial cerebral spinal fluid, CaCl2, and thrombin.

Memorial Sloan-Kettering C. difficile Infection Patent

Memorial Sloan-Kettering Cancer Center's patent application US20260108564A1 was published April 23, 2026, disclosing methods and compositions for reducing the risk and severity of C. difficile infection. Application No. 19303846 was filed August 19, 2025, naming Eric Pamer, Charlie Buffie, and Peter McKenney as inventors. The invention is based on the discovery that a restricted fraction of gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection through the biosynthesis of secondary bile acids.

Bacillus Amyloliquefaciens Feed Additive for Aquaculture

USPTO published Application US20260108567A1 on April 23, 2026, covering a feed additive combining Bacillus amyloliquefaciens and postbiotics of Lactobacillus paracasei for use in aquaculture. The application, filed October 22, 2024, names YU-FEN LIU, WEI-CHIH HUANG, and YU-HUNG LIN as inventors. CPC classifications include A61K 35/742, A23K 10/18, and A23K 10/30. This publication does not impose compliance obligations on other parties; it is an informational record of a pending intellectual property claim.

Method for Preparing Targeted Dermal Papilla Cell-Derived Exosomes, Exosome Product, Liquid Hair Growth Formulation

US Patent Application US20260108562A1, filed October 7, 2025 and published April 23, 2026, discloses a method for preparing targeted exosomes from dermal papilla cells (DPCs) isolated using cell surface marker CD133 from hair follicles of healthy donors in a xeno-free and serum-free environment, with exosomes possessing surface markers CD9, CD63, and CD81 isolated via tangential flow filtration or size exclusion chromatography. The application also covers a liquid hair growth formulation incorporating the resulting lyophilized exosome product. This represents an early-stage intellectual property filing in the hair growth and exosome therapeutics space with no compliance obligations currently in effect.

US Patent Application A1 - Fiber Probiotic Combination for Regulating Cholesterol

USPTO published patent application US20260108569A1 (A1) on April 23, 2026, for a composition combining at least one fiber and at least one probiotic for oral administration to regulate gut bacteria association with cholesterol levels. The five inventors are Marc Garcia-Gar cera, Sami Damak, Bernard Berger, Fabio Mainardi, and Clara Lucia Garcia-Rodenas. The application was filed on October 30, 2023, under application number 19123666, with CPC classifications spanning A61K compounds including prebiotics and dietary fibers.

Ascension Medical Biotechnology Primed EVs for Bone, Dental Defects

Ascension Medical Biotechnology Co., Ltd. has filed US Patent Application US20260108559A1 with the USPTO, published on 23 April 2026 (filed 23 October 2025). The application covers primed extracellular vesicle compositions comprising upregulated miRNA and a biologically or pharmaceutically acceptable carrier, alongside methods of producing the compositions via stem cell cultivation with Polygonum multiflorum Thunb extract, baicalin, and bone morphogenetic protein 6. Claims encompass therapeutic use for preventing, treating, or ameliorating bone defects and dental defects in subjects in need thereof.

Iron Octasaccharide Complexes for Companion Animal Therapy

USPTO published patent application US20260108551A1 on April 23, 2026, covering iron octasaccharide complexes for subcutaneous administration in methods of treating iron deficiency, particularly iron deficiency anaemia, in companion animals. The application, originally filed August 3, 2022, names three inventors: Hans B. Andreasen, Tobias S. Christensen, and Simon M. Guldberg. The invention extends to pharmaceutical compositions comprising an iron octasaccharide complex and a pharmaceutically acceptable carrier for veterinary therapeutic use.

Dendrobium Polysaccharides and Vancomycin Bacteria for Intestinal Treatment

The USPTO published patent application US20260108552A1 on April 23, 2026, filed by the Hong Kong Authentication Centre of Valuable Chinese Medicines (Application No. 19306545, filed August 21, 2025) covering therapeutic uses of Dendrobium polysaccharides and vancomycin-sensitive bacteria for intestinal disorders including inflammatory bowel disease.

Nicotinamide Mononucleotide Derivatives for Treatment and Prevention of Sickle Cell Disease

The USPTO has published patent application US20260108550A1, filed June 13, 2025 (Application No. 19237807), covering nicotinamide mononucleotide (NMN) derivatives of Formula (I) for use in treating and/or preventing red blood cell disorders, specifically sickle cell disease. Inventors include Guillaume Bermond, Laurent Garçon, Matthias Canault, and Cecile Cros. The application is classified under CPC codes A61K 31/706, A61K 31/198, and A61P 7/06.

Abelzeta Files Bispecific CAR Patent for CD20 and BCMA

Abelzeta Inc. filed US Patent Application US20260108556A1 covering bispecific chimeric antigen receptors (CARs) that simultaneously target CD20 and BCMA antigens. The CAR constructs comprise an anti-CD20 scFv, an anti-BCMA scFv, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The filing was submitted on October 13, 2025, under Application No. 19356548, and names six inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Xin Yao, Xiaobing Luo, and Yutian Wei. The claimed compositions are directed toward treating autoimmune disorders and cancer.

Magnesium Salts Composition for Topical Skin Inflammation

The USPTO published patent application US20260108553A1 on April 23, 2026, filed by Instituto de Dermatología Ignacio Umbert, S.L. The application covers a composition comprising at least one magnesium salt, at least one non-magnesium salt, at least one antioxidant, and at least one plant extract, intended for treating skin inflammation pathologies. CPC classifications span A61K categories including magnesium compounds, antioxidants, and botanical extracts.

Methods for Reprogramming and Gene Editing Cells

The USPTO published patent application US20260108554A1 on April 23, 2026, filed on May 1, 2023 under application number 18861162. The application names seven inventors — Matthew ANGEL, Christopher ROHDE, Ian HAY, Ismet Caglar TANRIKULU, Tae Yun KIM, Abigail BLATCHFORD, and Mackenzie PARMENTER — and covers improved methods for reprogramming and gene editing cells, including manufacturing lymphoid and myeloid lineage cell populations. CPC classifications span cell therapy (A61K), proteins (C07K), and gene editing technologies (C12N).

US20260108555A1 - Cell Memory Regulation Without Genetic Modification

Victor TETS and Georgy TETS filed US Patent Application 19335515 for products and methods regulating cell behavior, cell memory, and erasure of cell memory across medicine, biology, veterinary, pharmacology, diagnostics, agriculture, ecology, and biotechnology. The patent was published April 23, 2026 (US20260108555A1) with CPC classifications in A61K 35/17, A61K 35/15, A61K 35/19, A61P 35/00, and C12N 9/22. The application claims a novel method to control cell and organism properties without using mutagens, gene introduction, gene tools, or environmental changes — distinguishing it from prior art in cellular regulation and biomanufacturing.

Aminergic Phytocannabinoids Derivatives as Multi-Target Agents for Neurological Disorders

The University of South Carolina has filed patent application US20260108541A1 with the USPTO for aminergic phytocannabinoid derivatives as multi-target agents for treating neurological disorders in mammals including humans. The application covers CBD derivatives functionalized at position 7 and THC derivatives functionalized at position 11. Inventors are Juan Francisco Leon Oyola and Zachary I. Stryker.

Macrolide Compound Patent Application, Institute of Feed Research, Chinese Academy of Agricultural Science

The USPTO has published patent application US20260108549A1 for a macrolide compound, filed by the Institute of Feed Research under the Chinese Academy of Agricultural Sciences, with inventors Xiubo LI, Fei XU, Yiming LIU, and Xiaojie CHEN. The application, filed May 31, 2024, covers pharmaceutical and veterinary compositions containing the macrolide compound for treating pathogen infections, especially in animals. Patent applications are published to establish priority and allow public review of the invention.

Novel Liquid Oral CBD Formulations, Published Apr 23

The USPTO published patent application US20260108540A1 on April 23, 2026, covering stable liquid oral pharmaceutical formulations of synthetic Cannabidiol (CBD). The application, filed June 24, 2023 (Application No. 19120456), names inventors Chandrashekhar KOCHERLAKOTA and Srinivas ARUTLA. The formulations comprise synthetic CBD combined with pharmaceutical excipients including solvents, oils, organoleptic modifiers, buffers, and surfactants.

Tryptamine Compositions for Enhancing Neurite Outgrowth

US Patent Application US20260108544A1, filed February 7, 2025 and published April 23, 2026, covers neurotrophic and nootropic compositions comprising tryptamines from psilocybin-containing mushrooms, optionally combined with phenethylamines, amphetamines, erinacines, hericenones, and cannabinoids. The application names Paul Edward Stamets as inventor and lists multiple CPC classifications spanning pharmaceutical chemistry and botanical extracts. This publication makes the application publicly available for review and potential opposition prior to grant.

L-fucose Treats Infectious Diseases and Cancers - US20260108547A1

The USPTO has published patent application US20260108547A1, filed on October 4, 2023, disclosing methods for treating infectious diseases and cancers by administering L-fucose to a subject. The application names Eric LE-LAU as inventor and claims therapeutic uses of the monosaccharide L-fucose in medical treatments. This patent publication establishes prior art and may affect freedom-to-operate analyses for competing therapeutics developers.

Self-Emulsifying Cannabinoid Tablet Formulations by Fertin Pharma

Fertin Pharma A/S has filed USPTO Application US20260108543A1 for an orally dissolvable or chewable tableted powder formulation incorporating self-emulsifying systems loaded with at least 10% cannabinoids by weight. The formulation includes 20-80% water-soluble agents by weight, one or more flavors, and surfactants containing polyethylene glycol moieties. The application covers both liquid self-emulsifying systems (with surfactants, lipids, and isolated or synthetic cannabinoids) and solid self-emulsifying systems (with surfactants, waxes, and isolated or synthetic cannabinoids). Filing date was December 22, 2025.

Paeoniflorin-Isoliquiritigenin Composition Treats Pulmonary Fibrosis

The USPTO has published patent application US20260108548A1, assigned to Henan University of Chinese Medicine, covering a therapeutic composition of paeoniflorin and isoliquiritigenin for treating diffuse interstitial pulmonary fibrosis. The application was filed on October 8, 2023 (Application No. 19129203) and names nine inventors including Jiansheng Li and Peng Zhao. The composition is claimed to provide anti-inflammatory, antioxidant, and collagen deposition inhibition effects. Patent applications are informational publications — no examination or grant decision has been made.